Summary
The Southwest Oncology Group (SWOG) studied the response rate and toxicity of menogaril (200 mg/m2 i.v. q 28 days) in patients with advanced metastatic renal cell carcinoma. During the early stage of the trial two partial responses were seen in the first 20 treated patients, and an additional 36 evaluable patients were studied. Three of 56 (5%) evaluable patients achieved partial responses. Significant white cell toxicity was observed. Mild or moderate degrees of thrombocytopenia, gastrointestinal side effects, alopecia and phlebitis occurred. No cardiac toxicity was noted. The low response rate suggests that menogaril in this dose schedule has no role in the treatment of patients with advanced metastatic renal cancer.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Kruger WC, Pschigoda LM, Schpok SLF, Moscowitz A, McGovren JI, Neta P, Merritt MV, Li LH: The interaction of nogalamycin and analogs with DNA and other biopolymers. Chem-Biol. Interaction 36: 1–18, 1981
Li LH, Murch LL, Wooden JM, Krueger WC, Pschigoda LM: Inhibition of DNA and RNA polymerases by nogalamycin and its analogs. (Abstr) Proc Am Assoc Cancer Res 19: 30, 1978
Neil GL, Kuentzel SL, McGovren JP: Treatment of mouse tumors with 7-con-0-Methylnogarol and other analogs of the anthracycline antibiotics, nogalamycin. Cancer Treat Rep 63: 1971–1978, 1979
Bhuryan BK, McGovren JP, Crampton SL: Intracellular uptake of 7-con-O-Methylnogarol and Adriamycin by cells in culture and its relationship to cell survival. Cancer Res 41: 882–887, 1981
Dorr FA, VonHoff DD, Kuhn JG, Schwartz R, Krisner DL: Phase I clinical investigation of 7-con-0-Methylnogaril, a new anthracycline antibiotic. Cancer Res 46: 2562–2565, 1986
Dodion P, Sessa C, Joss R, Crespeigne N, Willems Y, Kitt M, Abrams J, Finet C, Brewer JE, Adams WJ, Earhart RH, Rozencweig M, Kenis Y, Cavalli F: Phase I study of intravenous menogaril administered intermittently. J Clin On-col 4: 767–774, 1986
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Stephens, R.L., Goodman, P., Crawford, E.D. et al. Evaluation of menogaril in renal cell carcinoma. Invest New Drugs 8 (Suppl 1), S69–S71 (1990). https://doi.org/10.1007/BF00171987
Issue Date:
DOI: https://doi.org/10.1007/BF00171987